Phase 2 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with mild to moderate open-angle glaucoma, mild to moderate normal-tension glaucoma, or stable non-proliferative diabetic retinopathy in at least one eye.
- People whose vision, even with glasses or contact lenses, meets a minimum level of 20/200 (as measured by a standard eye chart test) in each eye.
- People who are able and willing to sign a consent form and follow the study instructions throughout the trial.
Who may not be able to join:
- People who have a history of active eye disease other than the specific conditions listed above (mild to moderate open-angle glaucoma, mild to moderate normal-tension glaucoma, or stable non-proliferative diabetic retinopathy).
- People who are currently using more than one eye drop medication to lower eye pressure, unless any prior surgical or laser procedures to lower eye pressure were completed at least 3 months before the first study visit.
- People who have used a specific type of eye drop called a beta-blocker (for example, timolol) within the 3 months before the first study visit.
- People who have not been following their current eye pressure treatment as prescribed, or who are unwilling to do so during the study.
- People who have a serious retinal condition in either eye that is likely to need treatment during the study period, such as advanced diabetic eye disease or severe macular degeneration.
- People who have received anti-VEGF injections or steroid eye treatments within 3 months before the first study visit, or who are expected to need these treatments during the study (confirm with trial site for details around prior diabetic macular oedema history).
- People who have cornea damage or changes in either eye — such as scarring, cloudiness, or swelling — that would make accurate eye pressure measurements unreliable.
- People who have been diagnosed with a significant systemic or psychiatric illness — such as serious heart, lung, liver, kidney, or endocrine conditions, or myasthenia gravis — that could affect the study results or raise safety concerns. For kidney disease specifically, Stages 3–5 or a kidney filtration rate at or below a certain threshold would be grounds for exclusion (confirm specific values with trial site).
- People who are currently using calcium channel blocker medications.
- People whose blood pressure is unstable or poorly controlled — either too high or too low.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Barbara M Wirostko, MD, Qlaris Bio
Phone: 978-930-2103
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in blood flow to the posterior segment of the eye.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.